| 01-11-2011 : | JUBILANT Q2 FY2012 : REVENUE - RS. 1,048CRORE, UP 22% YOY ; EBITDA - RS. 241CRORE, UP 58% YOY; EBITDA MARGINS AT 23.0% AS AGAINST 17.8% IN Q2’FY11; PAT - RS. 79CRORE AFTER UNREALISED FE LOSS RS. 43CRORE IN Q2’FY12, UP 8% YOY |
 | The Board of Jubilant Life Sciences Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India met today to approve financial results for quarter and half year ending September 30, 2011. |
| 18-10-2011 : | NORGINE AND JUBILANT ANNOUNCE DISCOVERY COLLABORATION IN GASTROINTESTINAL THERAPEUTIC AREA |
| Norgine, a leading European speciality pharmaceutical company and Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd, an integrated pharma & life sciences company of India, announced today, that they have entered into a discovery partnership. The collaboration, spanning an initial period of 3 years will provide a platform for Norgine to develop multiple targets utilising Jubilant Biosys integrated drug discovery platform targeting gastrointestinal diseases. |
| 11-10-2011 : | JUBILANT STARTS COMMERCIAL PRODUCTION OF NIACINAMIDE & 3 CYANOPYRIDNE FROM THE NEW 10,000 TPA FACILITY |
| Jubilant Life Sciences Ltd, an integrated Pharma and Life Sciences Company and the largest Custom Research &
Manufacturing player out of India announced today that it has commissioned its manufacturing facility at SEZ in
Gujrat, India, and the commercial production of 10,000 TPA Niacinamide and 3-Cyanopyridine from its new
facility started earlier this month. |
| 14-09-2011 : | JUBILANT SIGNS A MULTI MILLION DOLLAR CONTRACT TO MANUFACTURE AN OTC WOMEN HEALTH PRODUCT |
| Jubilant Life Sciences Ltd, an integrated Pharma and Life Sciences Company and the largest Custom Research & Manufacturing player out of India announced today that its subsidiary, Jubilant HollisterStier, a leading contract manufacturer in North America has entered into a multi year contract with a leading US pharma company to manufacture a prominent over the counter (OTC) women health and personal care product at its Montreal facility in North America. |
| 12-09-2011 : | JUBILANT PARTNERS SEKAB FOR EUROPEAN MARKETS
|
| Jubilant Pharmaceuticals NV, based in Belgium, a subsidiary of India based Jubilant Life Sciences Limited, has appointed Sweden based SEKAB BioFuels & Chemicals AB as sales & marketing agent for two of its leading life science chemical products, Bio-Ethyl Acetate and Acetic Anhydride for the European markets. |
| 07-09-2011 : | JUBILANT RECEIVES ANDA APPROVAL FOR PANTOPRAZOLE DELAYED RELEASE TABLETS 20 MG & 40MG |
| Jubilant Life Sciences Ltd, an integrated Pharma and Life Sciences Company and the largest Custom Research & Manufacturing player out of India announced today that it has received Abbreviated New Drug Application approval for Pantoprazole Sodium Delayed Release Tablets 20mg & 40mg, a generic equivalent of Protonix*, from the US FDA (U.S. Food and Drug Administration). |
| 12-08-2011 : | JUBILANT SIGNS A LONG TERM SUPPLY AGREEMENT FOR A NEW PRODUCT
|
| Jubilant Life Sciences Ltd, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, announced today, that it has signed a long term supply agreement in Proprietary Products business with a leading international Life Sciences company. The total contract is valued at over US$ 80 mn to be supplied in 3 years from the quarter April –June 2012. |
| 09-08-2011 : | JUBILANT Q1 FY2012 WITNESSES STRONG ALL ROUND GROWTH EXPECTS GROWTH MOMENTUM TO CONTINUE |
| The Board of Jubilant Life Sciences Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India met today to approve financial results for Q1 FY2012. |
| 28-06-2011 : | JUBILANT ANNOUNCES DRUG DISCOVERY ALLIANCE IN NEUROSCIENCE
|
| Jubilant Discovery Services Inc., Bedminster, New Jersey, a Jubilant Life Sciences Company, announced today that it has entered into a drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium, that will aim to deliver preclinical candidates to Janssen. The alliance is set to span an initial period of 3 years and will focus on multiple targets in the area of neuroscience. |
| 23-06-2011 : | JUBILANT AND ASTRAZENECA ANNOUNCE SUCCESSFUL DELIVERY OF EARLY MILESTONES IN DRUG DISCOVERY |
| Jubilant Biosys Ltd., Bengaluru, based subsidiary of Jubilant Life Sciences Ltd., and AstraZeneca, today announced another successful delivery of an early stage milestone in the Pain therapeutic area. |
| 20-06-2011 : | JUBILANT AND ENDO PHARMACEUTICALS ANNOUNCE LATE STAGE DISCOVERY MILESTONE IN ONCOLOGY PROGRAM |
| Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd., and Endo Pharmaceuticals (Nasdaq: ENDP), of Chadds Ford, Pa, U.S.A., announced today that they have achieved a late stage discovery milestone in their joint program focused on cancer. |
| 03-06-2011 : | JUBILANT RECEIVES USFDA APPROVAL FOR DONEPEZIL HYDROCHLORIDE TABLETS 5MG & 10 MG |
| Jubilant Life Sciences Ltd, an integrated Pharma and Life Sciences Company and the largest Custom Research & Manufacturing player out of India announced today that it has received approval from the U.S. Food and Drug Administration (US FDA) for Donepezil Hydrochloride Tablets 5 mg and 10 mg, a generic equivalent of Aricept®. |
| 02-06-2011 : | JUBILANT SUBSIDIARY CADISTA FILES REGISTRATION STATEMENT WITH SEC, USA
|
| Jubilant Life Sciences Ltd, an integrated Pharma and Life Sciences Company and the largest Custom Research & Manufacturing player out of India, announced today that its subsidiary, Cadista Holdings Inc. (Cadista) has filed a Registration Statement on Form 10 – General Form for Registration of Securities with the Securities and Exchange Commission (SEC), USA, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). |
| 23-05-2011 : | JUBILANT REPAYS US$ 202MN FOR OUTSTANDING FCCBS INCLUDING YTM OF US$60MN |
| Jubilant Life Sciences Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, today announced the prompt repayment of US$ 202 million on account of outstanding FCCBs including YTM of US$ 60 million. With this repayment, no more FCCBs are outstanding in the books. |
| 10-05-2011 : | Q4 FY2011: NET SALES - RS. 890 CRORE; EBITDA - RS. 137 CRORE; PAT - RS. 62 CRORE AND FOR FY2011: NET SALES - RS. 3,433 CRORE; EBITDA - RS. 567 CRORE; PAT - RS. 230 CRORE
|
| Board of Jubilant Life Sciences Limited (formerly Jubilant Organosys Ltd), an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India met today to approve its financial results for Q4 FY2011. |
| 08-03-2011 : | JUBILANT SETS UP GLOBAL SCALE CAPACITIES FOR SYMTET DEVELOPED THROUGH INHOUSE R&D |
| Jubilant Life Sciences Ltd (formerly Jubilant Organosys Ltd) an integrated Pharma and Life Sciences company and the largest Custom Research & Manufacturing player out of India, announced today that it is setting up a manufacturing plant for "2,3,5,6-Tetra Chloro Pyridine" (also commercially known as Symtet/TCP) of 24,000 TPA capacity and Chlorinated Pyridine derivatives of 5,000 TPA,in Special Economic Zone, at Bharuch, Gujrat. |
| 14-02-2011 : | Q3 FY2011- NET SALES - RS. 867 CRORE ; EBITDA - RS. 134 CRORE ;PAT - RS. 44 CRORE |
| Board of Jubilant Life Sciences Limited (formerly Jubilant Organosys Ltd), an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India met today to approve its financial results for Q3 FY2011. |
